By Hongyun Huang, Ziad M. Al Zoubi, Gustavo Moviglia, Hari Shanker Sharma, Anna Sarnowska, Paul R. Sanberg, Lin Chen, Qun Xue, Dario Siniscalco, Shiqing Feng, Hooshang Saberi, Xiaoling Guo, Mengzhou Xue, Milan R. Dimitrijevic, Russell J. Andrews, Gengsheng Mao, Robert Chunhua Zhao, Fabin Han.
Published in Journal of Neurorestoratology, Volume 10, Issue 3, 2022, 100015, ISSN 2324-2426, https://doi.org/10.1016/j.jnrt.2022.100015
Cell therapy has been shown to be a crucial clinical therapeutic option for central nervous system diseases or damage. Promoting standardization of clinical cell therapy procedures is essential for professional associations devoted to cell therapy. The International Association of Neurorestoratology (IANR) and the Chinese Association of Neurorestoratology (CANR; Preparatory) collaborated to release Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017) in 2018. Due to recent advances and achievements in clinical cell therapy worldwide in recent years, IANR and CANR have renewed and updated the guidelines. Except for the requirements of equipment, personnel, and ethics, these revised guidelines include cell type nomenclature, cell quality control, cell types in clinical application, minimal suggested cellular doses, patient-informed consent, indications and contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, the policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility. IANR/CANR recommends that all clinical practitioners follow these cellular therapy guidelines. These guidelines provide references of better cell types, doses, routes, and therapeutic timing windows in different diseases.